RxDoctor Payments Data

Vanessa Mirabbasi, NP

Family · Las Vegas, NVNPI 1932362480

Payments from drug & device makers

$545in general payments, 2019–2025

Across 22 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$237
  • Penumbra, Inc.$115
  • Convatec Inc.$47
  • Pfizer$45
  • Nevro Corp.$45
  • AbbVie$25
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Collegium Pharmaceutical, Inc.13$237
Penumbra, Inc.1$115
Convatec Inc.1$47
Pfizer3$45
Nevro Corp.1$45
AbbVie1$25
Stryker1$24
Electronic Waveform Lab, Inc.1$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$545 in reported general payments places this provider in the 55th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$63,015
Medicare patients
222
Services billed
1,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine130$29,099
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen820$21,354
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen627$19,611
Xtampza ErOxycodone Myristate40$15,208
Oxymorphone Hcl ErOxymorphone Hcl19$14,323
BelbucaBuprenorphine Hcl18$11,823
OxycontinOxycodone Hcl19$10,251
Morphine Sulfate ErMorphine Sulfate316$8,471
Oxycodone Hcl430$7,592
Gabapentin296$4,342
Pregabalin154$2,709
Lidocaine40$2,670
Tizanidine Hcl205$2,088
Naloxone Hcl33$2,019
Baclofen147$1,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$237$27,03158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →